Table 1.
Patient demographics and baseline characteristics.
| Characteristic, N (%) unless stated | Total N = 47 |
|---|---|
| Sex | |
| Male | 0 |
| Female | 47 (100) |
| Ethnicity | |
| Caucasian/White | 41 (87.2) |
| Non-Caucasian/non-White | 3 (6.4) |
| Age, years; median (range) | 48.0 (35–73) |
| Baseline ECOG PS | |
| 0 | 25 (53.2) |
| 1 | 22 (46.8) |
| Prior anticancer therapy | |
| Chemotherapy | 45 (95.7) |
| Immunotherapy | 1 (2.1) |
| Other | 11 (23.4) |
| Missing | 2 (4.3) |
| Number of previous anticancer therapy regimens | |
| Neoadjuvant | 16 (34.0) |
| Adjuvant | 27 (57.4) |
| 1st line, metastatic disease | 24 (51.1) |
| 2nd line, metastatic disease | 10 (21.3) |
| >2nd line, metastatic disease | 5 (10.6) |
| Missing | 2 (4.3) |
| TP53a | |
| Wild type | 2 (4.3) |
| Mutant | 34 (72.3) |
| Missing | 11 (23.4) |
| BRCA1/2b | |
| Wild type | 31 (66) |
| Mutant | 5 (10.6) |
| Missing | 11 (23.4) |
| Basal subtypec | |
| Yes | 36 (76.6) |
| No | 7 (14.9) |
| Missing | 4 (8.5) |
ATM ataxia-telangiectasia mutated, BRCA1/2 breast cancer gene 1/2, ECOG PS Eastern Cooperative Oncology Group Performance Status, TP53 tumor protein 53.
aOnly patients with biomarker status determined by FoundationOne® CDx next generation sequencing were reported.
bPatients with unknown BRCA1/2 status were prospectively tested at screening by BRCAnalysis assay (Myriad Genetics); patients that were found to be BRCA1/2 germline mutant were still enrolled in the study.
cAssessment for basal subtype was performed retrospectively via PAM50 analysis (Prosigna).